These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 17610503)
1. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice. Justesen S; Buus S; Claesson MH; Pedersen AE Immunology; 2007 Nov; 122(3):326-34. PubMed ID: 17610503 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Shibagaki N; Udey MC Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050 [TBL] [Abstract][Full Text] [Related]
3. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells. Viehl CT; Tanaka Y; Chen T; Frey DM; Tran A; Fleming TP; Eberlein TJ; Goedegebuure PS Breast Cancer Res Treat; 2005 Jun; 91(3):271-8. PubMed ID: 15952060 [TBL] [Abstract][Full Text] [Related]
4. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Nikitina EY; Clark JI; Van Beynen J; Chada S; Virmani AK; Carbone DP; Gabrilovich DI Clin Cancer Res; 2001 Jan; 7(1):127-35. PubMed ID: 11205900 [TBL] [Abstract][Full Text] [Related]
6. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL. Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015 [TBL] [Abstract][Full Text] [Related]
7. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380 [TBL] [Abstract][Full Text] [Related]
8. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201 [TBL] [Abstract][Full Text] [Related]
9. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells. Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203 [TBL] [Abstract][Full Text] [Related]
10. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice. Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292 [TBL] [Abstract][Full Text] [Related]
11. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Kuball J; Schuler M; Antunes Ferreira E; Herr W; Neumann M; Obenauer-Kutner L; Westreich L; Huber C; Wölfel T; Theobald M Gene Ther; 2002 Jul; 9(13):833-43. PubMed ID: 12080377 [TBL] [Abstract][Full Text] [Related]
12. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583 [TBL] [Abstract][Full Text] [Related]
13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
14. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698 [TBL] [Abstract][Full Text] [Related]
15. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831 [TBL] [Abstract][Full Text] [Related]
16. A tat fusion protein-based tumor vaccine for breast cancer. Viehl CT; Becker-Hapak M; Lewis JS; Tanaka Y; Liyanage UK; Linehan DC; Eberlein TJ; Goedegebuure PS Ann Surg Oncol; 2005 Jul; 12(7):517-25. PubMed ID: 15889213 [TBL] [Abstract][Full Text] [Related]
17. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice. Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388 [TBL] [Abstract][Full Text] [Related]
19. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity. Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514 [TBL] [Abstract][Full Text] [Related]
20. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]